secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2021-07-29T23:59:59+00:00
Accession:  0001628280-21-014888
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corcept Q2 revenue $91.6M; GAAP EPS $0.21; reiterates 2021 guidance $355-385M
-----------------------------------------------------------------------------

- Revenue $91.6M (+3.4% YoY); GAAP diluted EPS $0.21 vs $0.23; non-GAAP EPS $0.30 vs $0.32.
- Cash and investments $471.6M, +$16.8M from Q1; repurchased 1.4M shares for $30.8M.
- 2021 revenue guidance reaffirmed at $355-385M; CEO cites easing COVID restrictions driving growth.
- Phase 3 pivotal trial of relacorilant in platinum-resistant ovarian cancer expected to start Q1 2022.
- GRACE Phase 3 trial for relacorilant in Cushing's syndrome continues; NDA submission planned Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000162828021014888/0001628280-21-014888-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000162828021014888/cort-20210729.htm
  HTML page:      https://secwatch.observer/filing/0001628280-21-014888

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer